The Antitrust Prescription
The Antitrust Prescription covers antitrust and other economic issues affecting companies in the pharmaceutical industry. In this blog, Edgeworth’s experts provide legal practitioners and pharmaceutical company leaders with the latest economic insights and information impacting business in this constantly-evolving industry.
- Blog, Bloomberg Law | 07.11.2024
Edgeworth experts Dr. George Korenko and Dr. Tram Nguyen describe FTC actions and recent court decisions and how they affect the recent state of economic analysis of antitrust impact for these alleged patent practices in the pharmaceutical industry.
- Blog, ABA Antitrust Law Section | 06.13.2024
The Federal Trade Commission (FTC) and U.S. Department of Justice (DOJ) are continually focused on investigating the impact of consolidation in healthcare. More recently, the agencies have expressed a renewed interest in for-profit medicine.
- Blog, 03.04.2024
The 340B Drug Pricing Program is designed to increase access to affordable drugs for vulnerable patient populations. However, the success of the program and the complexity of the Medicaid Drug Rebate Program could result in the unintended effect of needlessly increasing costs to drug manufacturers and states.
- Blog, 11.29.2023
In the latest article for The Antritrust Prescription, Edgeworth Managing Principal Dr. Ashley Zhou examines recent enforcement concerning the listing of patents in the FDA's Orange Book and potential economic implications of new enforcement efforts.